Energenesis Biomedical CO.,LTD. (TPE:6657)

Market Cap	2.66B -52.0%
Revenue (ttm)	7.85M +3.9%
Net Income	-207.74M
EPS	-2.35
Shares Out	87.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,500
Open	30.85
Previous Close	30.25
Day's Range	29.00 - 30.85
52-Week Range	29.00 - 63.00
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 35
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6657

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 30, 2026

Data Sources Report a data error